Muscle wasting in COPD

International Journal of Respiratory Care

Volumn 5, Issue 2, 2009, Pages 40-43

  Rutten, Erica P A ^a   Wouters, E F M ^b  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GHRELIN; MEGESTROL; REACTIVE OXYGEN METABOLITE; SOMATOMEDIN C; TESTOSTERONE; TUMOR NECROSIS FACTOR ALPHA;

AMINO ACID METABOLISM; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE COURSE; ENDOCRINE DISEASE; ENZYME ACTIVITY; EXERCISE TOLERANCE; FRAGILITY FRACTURE; HUMAN; HUMAN TISSUE; HYPOXIA; INCREASED APPETITE; INFLAMMATION; LUNG FUNCTION TEST; MUSCLE ATROPHY; MUSCLE WEAKNESS; PRACTICE GUIDELINE; PREDICTION; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SURVIVAL; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 70350150475     PISSN: 17471273     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Wouters EF. Approaches to improving health status in chronic obstructive pulmonary disease: one or several? Proc Am Thorac Soc 2006; 3: 262-269.
2. Halpin DM. Assessing the severity of COPD. Prim Care Respir J 2006; 15: 78-80.
3. Cote CG, Cekki BR. Pulmonary rehabilitation and the BODE index in COPD. Eur Respir J 2005; 26: 630-636.
4. Beaufrere B, Morio B. Fat and protein redistribution with aging: metabolic considerations. Eur J Clin Nutr 2000; 54(Suppl 3): S48-S53. (Pubitemid 30447300)
5. Deschenes MR. Effects of aging on muscle fibre type and size. Sports Med 2004; 34: 809-824.
6. Morse CI, Thom JM, Birch KM, Narici MV. Changes in triceps surae muscle architecture with sarcopenia. Acta Physiol Scand 2005; 183: 291-298. (Pubitemid 40387105)
7. Volpi E, Nazemi R, Fujita S. Muscle tissue changes with aging. Curr Opin Clin Nutr Metab Care 2004; 7: 405-410.
8. Schols AMWJ, Soeters PB, Dingemans AMC, et al. Prevalence and characteristics of nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitation. Am Rev Respir Dis 1993; 147: 1151-1156.
9. Vermeeren MA, Creutzberg EC, Schols AM, et al. Prevalence of nutritional depletion in a large out-patent population of patients with COPD. Respir Med 2006; 100: 1349-1355.
10. Franssen FM, Wouters EF, Baarends EM, Akkermans MA, Schols AM. Arm mechanical efficiency and arm exercise capacity are relatively preserved in chronic obstructive pulmonary disease. Med Sci Sports Exerc 2002; 34: 1570-1576.
11. Baarends EM, Schols AM, Mostert R, Wouters EF. Peak exercise response in relation to tissue depletion in patients with chronic obstructive pulmonary disease. Eur Respir J 1997; 10: 2807-2813. (Pubitemid 28052792)
12. Gosker HR, Kubat B, Schaart G, et al. Myopathological features in skeletal muscle of patients with chronic obstructive pulmonary disease. Eur Respir J 2003; 22: 280-285. (Pubitemid 36986998)
13. Mostert R, Goris A, Weling-Scheepers C, Wouters EF, Schols AM. Tissue depletion and health related quality of life in patients with chronic obstructive pulmonary disease. Respir Med 2000; 94: 859-867. (Pubitemid 30734060)
14. Schols AMWJ, Slangen J, Volovics L, Wouters EFM. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 1791-1797. (Pubitemid 28311260)
15. Vestbo J, Prescott E, Almdal T, et al. Body mass, fat-free body mass, and prognosis in patients with chronic obstructive pulmonary disease from a random population sample: findings from the Copenhagen City Heart Study. Am J Respir Crit Care Med 2006; 173: 79-83. (Pubitemid 43069791)
16. Marquis K, Debigare R, Lacasse Y, et al. Midthigh muscle cross-sectional area is a better predictor of mortality than body mass index in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166: 809-813.
17. Hopkinson NS, Tennant RC, Dayer MJ, et al. A prospective study of decline in fat free mass and skeletal muscle strength in chronic obstructive pulmonary disease. Respir Res 2007; 8: 25.
18. Decramer M, Lacquet LM, Fagard R, Reglers P. Corticosteroids contribute to muscle weakness in chronic airflow obstruction. Am J Respir Crit Care Med 1994; 150: 11-16. (Pubitemid 24209929)
19. Spruit MA, Gosselink R, Troosters T, et al. Muscle force during an acute exacerbation in hospitalised patients with COPD and its relationship with CXCL8 and IGF-I. Thorax 2003; 58: 752-756. (Pubitemid 37094049)
20. Creutzberg EC, Wouters EF, Vanderhoven-Augustin IM, Dentener MA, Schols AM. Disturbances in leptin metabolism are related to energy imbalance during acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 162: 1239-1245.
21. Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004; 59: 574-580. (Pubitemid 38901515)
22. Broekhuizen R, Grimble RF, Howell WM, et al. Pulmonary cachexia, systemic inflammatory profile, and the interieukln 1beta -511 single nucleotide polymorphism. Am J Clin Nutr 2005; 82: 1059-1064. (Pubitemid 43779765)
23. Schols AM, Buurman WA, Staal van den Brekel AJ, Dentener MA, Wouters EF. Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. Thorax 1996; 51: 819-824.
24. Takabatake N, Nakamura H, Abe S, et al. The relationship between chronic hypoxemia and activation of the tumor necrosis factor-alpha system in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161: 1179-1184. (Pubitemid 30243827)
25. Langen RC, Schols AM, Kelders MC, Wouters EF, Janssen-Heininger YM. Inflammatory cytokines inhibit myogenic differentiation through activation of nuclear factor-kappaB. Faseb J 2001; 15: 1169-1180.
26. Vemooy JH, Kucukaycan M, Jacobs JA, et al. Local and systemic inflammation in patients with chronic obstructive pulmonary disease: soluble tumor necrosis factor receptors are increased in sputum. Am J Respir Crit Care Med 2002; 166: 1218-1224. (Pubitemid 35222599)
27. Langen RC, Schols AM, Kelders MC, et al. Muscle wasting and impaired muscle regeneration in a murine model of chronic pulmonary inflammation. Am J Respir Cell Mol Biol 2006; 35: 689-696.
28. Langen RC, Kom SH, Wouters EF. ROS in the local and systemic pathogenesis of COPD. Free Radic Biol Med 2003; 35: 226-235.
29. Engelen MPKJ, Schols AMWJ, Does JD, Deutz NEP, Wouters EFM. Altered glutamate metabolism is associated with reduced muscle glutathione levels in patients with emphysema. Am J Respir Crit Care Med 2000; 161: 98-103.
30. Gosker HR, Bast A, Haenen GR, et al. Altered antioxidant status in peripheral skeletal muscle of patients with COPD. Respir Med 2005; 99: 118-125. (Pubitemid 40017395)
31. Mercken EM, Hageman GJ, Schols AM, et al. Rehabilitation decreases exercise-induced oxidative stress in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 172: 994-1001. (Pubitemid 41476536)
32. Van Helvoort HA, Heijdra YF, Thijs HM et al. Exercise-induced systemic effects in muscle-wasted patients with COPD. Med Sci Sports Exerc 2006; 38: 1543-1552. (Pubitemid 44373772)
33. Couillard A, Prefaut C. From muscle disuse to myopathy in COPD: potential contribution of oxidative stress. Eur Respir J 2005; 26: 703-719. (Pubitemid 41448671)
34. Debigare R, Marquis K, Cote CH, et al. Catabolic/anabolic balance and muscle wasting in patients with COPD. Chest 2003; 124: 83-89. (Pubitemid 36851335)
35. Van Vliet M, Spruit MA, Verleden G, et al. Hypogonadism, quadriceps weakness, and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 172: 1105-1111. (Pubitemid 43066645)
36. Casaburi R, Bhasin S, Cosentino L, et al. Effects of testosterone and resistance training in men with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170: 870-878. (Pubitemid 39346482)
37. Svartberg J, Aasebo U, Hjalmarsen A, Sundsfjord J, Jorde R. Testosterone treatment improves body composition and sexual function in men with COPD, in a 6-month randomized controlled trial. Respir Med 2004; 98: 906-913. (Pubitemid 39069342)
38. Ferreira IM, Verreschi IT, Nery LE, et al. The influence of 6 months of oral anabolic steroids on body mass and respiratory muscles in undernourished COPD patients. Chest 1998; 114: 19-28.
39. Welsberg J, Wanger J, Olson J, et al. Megestrol acetate stimulates weight gain and ventilation in underweight COPD patients. Chest 2002; 121: 1070-1078. (Pubitemid 34280424)
40. Nagaya N, Itoh T, Murakami S, et al. Treatment of cachexia with ghrelin in patients with COPD. Chest 2005; 128: 1187-1193. (Pubitemid 41324394)
41. Pitta F, Troosters T, Spruit MA, et al. Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 171: 972-977. (Pubitemid 40616945)
42. Franssen FM, Wouters EF, Schols AM. The contribution of starvation, deconditioning and ageing to the observed alterations in peripheral skeletal muscle in chronic organ diseases. Clin Nutr 2002; 21: 1-14.
43. Maltais F, Simard AA, Simard C, et al. Oxidative capacity of the skeletal muscle and lactic acid kinetics during exercise in normal subjects and in patients with COPD. Am J Respir Crit Care Med 1996; 153: 288-293. (Pubitemid 26026864)
44. Gosker HR, van Mameren H, van Dijk PJ, et al. Skeletal muscle fibre-type shifting and metabolic profile in patients with chronic obstructive pulmonary disease. Eur Respir J 2002; 19: 617-625. (Pubitemid 34285157)
45. Gosker H, Zeegers M, Wouters E, Schols AM. Muscle fibre type shifting in the vastus lateralis of patients with COPD is associated with disease severity: a systematic review and meta-analysis. Thorax 2007; 62: 944-949. (Pubitemid 350084491)
46. Engelen MP, Deutz NE, Wouters EF, Schols AM. Enhanced levels of whole-body protein turnover in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 62: 1488-1492. (Pubitemid 30826176)
47. Rutten EP, Franssen FM, Engelen MP, et al. Greater whole-body myofibrillar protein breakdown in cachectic patients with chronic obstructive pulmonary disease. Am J Clin Nutr 2006; 83: 829-834. (Pubitemid 44713147)
48. Bolton CE, Broekhuizen R, Ionescu AA, et al. Cellular protein breakdown and systemic inflammation are unaffected by pulmonary rehabilitation in COPD. Thorax 2007; 62: 109-114. (Pubitemid 46271715)
49. Gosker HR, Engelen MP, van Mameren H, et al. Muscle fiber type IIX atrophy is involved in the loss of fat-free mass in chronic obstructive pulmonary disease. Am J Clin Nutr 2002; 76: 113-119.
50. Hofford JM, Milakofsky L, Vogel WH, et al. The nutritional status in advanced emphysema associated with chronic bronchitis. A study of amino acid and catecholamine levels. Am Rev Respir Dis 1990; 141: 902-908.
51. Morrison WL, Gibson JNA, Scrimgeour C, Rennie MJ. Muscle wasting in emphysema. Clin Sci 1988; 75: 415-420.
52. Schols AMWJ, Deutz NEP, Mostert R, Wouters EFM. Plasma amino acid levels in patients with chronic obstructive pulmonary disease. Monaldi Arch Chest Med 1993; 48: 546-548. (Pubitemid 24039923)
53. Engelen MP, Wouters EF, Deutz NE, Menheere PP, Schols AM. Factors contributing to alterations in skeletal muscle and plasma amino acid profiles in patients with chronic obstructive pulmonary disease. Am J Clin Nutr 2000; 72: 1480-1487.
54. Rutten EP, Engelen MP, Schols AM, Deutz NE. Skeletal muscle glutamate metabolism in health and disease: state of the art. Curr Opin Clin Nutr Metab Care 2005; 8: 41-51. (Pubitemid 40204444)
55. Agusti A, Morla M, Sauleda J, Saus C, Busquets X. NF-kappaB activation and iNOS upregulation in skeletal muscle of patients with COPD and low body weight. Thorax 2004; 59: 483-487. (Pubitemid 38797520)